Showing results (871-880 of 1,095) with videos related to

Sort By:
Pageof 110
Clinical Lung Cancer|January 25, 2025
Kirsten Rat Sarcoma Virus Mutations Effect On Tumor Doubling Time And Prognosis Of Solid Dominant Stage I Lung AdenocarcinomaRiccardo Tajè, Vincenzo Ambrogi, Federico Tacconi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesotheliomaJoanna Kopecka, Iris C Salaroglio, Luisella Righi, et al.
The Lancet. Oncology|May 14, 2018
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trialVanesa Gregorc, Rabab M Gaafar, Adolfo Favaretto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancerSuresh S Ramalingam, David R Spigel, David Chen, et al.
JTO Clinical and Research Reports|September 30, 2021
The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung CancerBarbara J Gitlitz, Silvia Novello, Tiziana Vavalà, et al.
Lung Cancer (Amsterdam, Netherlands)|June 3, 2020
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer expertsM Früh, C M Panje, M Reck, et al.
Critical Reviews in Oncology/Hematology|December 20, 2020
Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second waveValentina Bertaglia, Maria Lucia Reale, Paolo Bironzo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 15, 2014
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancerG V Scagliotti, I Bondarenko, F Blackhall, et al.
Journal of Personalized Medicine|April 27, 2024
BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology ReportGiulio Rossi, Luisella Righi, Francesca Barbisan, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2020
Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomasEnrico Franceschi, Alicia Tosoni, Stefania Bartolini, et al.
Pageof 110